A Phase 1/2 interventional study of TBS-2025 in Acute Myeloid Leukemia, sponsored by TuHURA Biosciences, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by TuHURA Biosciences, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this interventional study is to learn if TBS-2025 is safe to administer to participants with relapsed/refractory (r/r) Acute Myeloid Leukemia (AML). The main questions it aims to answer are:
Participants will:
This is an open label Phase 1b study evaluating the safety, tolerability, PK, PD, and preliminary efficacy of TBS-2025 in adult patients with r/r NPM1-mutant (r/r defined as per ELN2022) that is resistant to or has relapsed following approved therapies (or are intolerant) and for whom there are no suitable effective therapies. The study is composed of sequential cohorts: a D-E Monotherapy Cohort to assess multiple dose levels and a D-O Monotherapy Cohort to further assess the optimal dose in at least 2 randomly assigned groups.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
This study's planned enrollment of 55 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →TuHURA Biosciences, Inc. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TBS-2025 administered at multiple, escalating dose levels as monotherapy
Biological: TBS-2025
TBS-2025 administered at 2 or more dose levels as monotherapy
Biological: TBS-2025
TBS-2025 is a fully human IgG1-kappa monoclonal antibody that binds specifically to the hVISTA-ECD and blocks interaction with endogenous VISTA ligands.
Also known as: trovostobart
Number of participants with dose limiting toxicities (DLTs)
Time frame: At the end of Cycle 1 ( each cycle is 28 days)
Number of participants with an AE
Time frame: Baseline through study completion, an average of 2 years
Pharmacokinetic (PK) Serum Concentration of TBS-2025
Time frame: Baseline through the start of Cycle 4 (each cycle is 28 days)
Number of participants with anti-TBS-2025 antibody formation
Time frame: Baseline through the end of Cycle 4 (each cycle is 28 days)
Rate of Complete Remission
Time frame: Baseline to study completion, an average of 2 years
Duration of Response
Time frame: Baseline to study completion, an average of 2 years
Time to Response
Time frame: Baseline to study completion, an average of 2 years
Morphological Leukemia Free State Rate
Time frame: Baseline to study completion, an average of 2 years
Rate of Composite Complete Remission
Time frame: Baseline to study completion, an average of 2 years
Overall Response Rate
Time frame: Baseline to study completion, an average of 2 years
Event-Free Survival
Time frame: Baseline to study completion, an average of 2 years
Minimal Residual Disease Negativity Rate
Time frame: Baseline to study completion, an average of 2 years
Overall Survival
Time frame: Baseline to study completion, an average of 2 years
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 24 months is below that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TuHURA Biosciences, Inc.